Disodium cromoglycate: laboratory studies and clinical trial in allergic rhinitis

Abstract

Summary The ability of disodium cromoglycate (DSCG) to block allergic responses in the nasal airways was investigated in two ways. The effect of DSCG on antigen‐induced airways resistance changes in sensitive subjects was investigated in the laboratory. DSCG in a dose of 10 mg applied to each nostril was shown to block the expected reaction in 71 % of subjects and a 1 mg dose in 47%. Protection was conferred against antigen challenge for a period of about 6 hr by the 10 mg dose. A clinical trial of DSCG (10 mg) in seasonal allergic rhinitis was carried out using a double‐blind cross‐over design. Analysis of the results showed significant DSCG protective effects against lower respiratory tract symptoms and a significant antihistamine sparing effect. Analysis of part of the trial period when antigen challenge was uniformly high showed significant DSCG protective effects against sneezing, nasal discharge and nasal obstruction. Nasal application of DSCG is considered to be a promising alternative therapeutic approach in allergic rhinitis.